Skip to main content
National Cancer Prevention Month: Rising Trends and How to Combat Them With Samuel Kareff, Matthew Hadfield, Waqas Haque, and Joseph Kalis
Keira Smith
Expert Analysis
In honor of National Cancer Prevention Month 2024, members of the Oncology Data Advisor Editorial Board and Fellows Forum sat down for a panel discussion about the rising incidence of cancer diagnoses, factors contributing to them, and how to counsel patients in light of these emerging trends.  
Osimertinib Plus Platinum-Based Chemotherapy Approved for Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Lyn Brook
FDA Updates
The FDA has granted approval to osimertinib (Tagrisso®, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. &nbs...
Lifileucel Granted Accelerated Approval for Unresectable or Metastatic Melanoma
Lyn Brook
FDA Updates
The FDA has granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) for adult patients with unresectable or metastatic melanoma previously treated with a programmed cell death protein 1 (PD-1) blocking antibody, and if BRAF V600–positive, a BRAF inhibitor with or without a mitogen-activated protein kinase (MEK) inhibitor...
Tepotinib Granted Traditional Approval for Metastatic Non–Small Cell Lung Cancer
Lyn Brook
FDA Updates
The FDA has granted traditional approval to tepotinib (Tepmetko®, EMD Serono, Inc.) for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Tepotinib was previously granted accelerated approval for this indication on February 3, 2021.   Why it matters...
Addressing Knowledge Gaps in the Treatment of Advanced Endometrial Cancer
Lyn Brook
Practice Patterns
Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding emerging checkpoint inhibitor–based strategies for advanced endometrial cancer.   Cancer of the uterine corpus is the most common cancer of the female genital tract, with an estimated 67,880 new cases diagnosed and 13,250...
Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options With Waqas Haque, MD, MPH, and Matthew Hadfield, DO
Keira Smith
Expert Analysis
In honor of Gallbladder and Bile Duct Cancer Awareness Month this February, Fellows Forum members Dr. Waqas Haque and Dr. Matthew Hadfield sat down for a discussion on the challenges in diagnosis of gallbladder and bile duct cancers and the importance of genetic sequencing for making targeted treatments available for patients.   Waqas Haque, M...
Updates on AI and Deep Learning for Cancer Detection and Outcomes Prediction
Keira Smith
Expert Analysis
By Waqas Haque, MD, MPH In this latest edition of The Way Ahead: The Convergence of Technology and Cancer Care, Dr. Waqas Haque shares his perspectives on a deep learning model for gallbladder cancer detection, a precision medicine platform for pancreatic ductal adenocarcinoma outcome prediction, and more!  
World Cancer Day 2024 With Oncology Data Advisor
Keira Smith
Expert Analysis
In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular testing, clinical trial diversity, and patient advocacy worldwide.  
National Cancer Prevention Month: Lowering Prostate Cancer Risk With Stephen Freedland, MD, and William Aronson, MD
Keira Smith
Expert Analysis
In honor of National Cancer Prevention Month, Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, sat down with Dr. William Aronson, Professor of Urology at the University of California, Los Angeles (UCLA) and Chief of Urologic Oncology at the West Los Angeles Veterans Affairs (VA) Medical Center for a conversation about the multitude of factors under investigation for prostate cancer prevention. Dr. Freedland and Dr. Aronson discuss prostate-specific antigen (PSA) screening recommendations, medications being investigated, the roles of diet and exercise, and how they personally counsel their patients regarding prostate cancer prevention and risk reduction.  
Racial and Socioeconomic Disparities in the CLL Community Oncology Setting With Ira Zackon, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD, a Senior Medical Director with Ontada, to discuss his abstract and presentation about racial a...
Guiding Dietary Choices During Multiple Myeloma Treatment With Richa Parikh, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Guiding Dietary Choices During Multiple Myeloma Treatment: Richa Parikh, MD In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow at Karmanos Cancer Institute, discusses her team's study investigating the role of diet in multiple myeloma and how its findings can be used to help guide dietary decisions for patients.  
Highlights of Multiple Myeloma Research Presented at ASH With Urvi Shah, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Highlights of Multiple Myeloma Research Presented at ASH 2023: Urvi Shah, MD At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment!  
Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma With Swetha Kambhampati, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Swetha Kambhampati, MD At the recent American Society of Hematology (ASH) Annual Meeting, Swetha Kambhampati, an Assistant Professor in the Division of Lymphoma at City of Hope, sat down with Oncology Data Advisor to further discuss her pr...
Managing Acute Leukemias and Lymphomas When Patients Stay Local With Dipti Patel-Donnelly, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Managing Acute Leukemias and Lymphomas When Patients Stay Local: Dipti Patel-Donnelly, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Dipti Patel-Donnelly, a Medical Oncology at Virginia Cancer Specialists, hosted a session highlighting how to optimize management when patients with hema...
Improving Quality of Life in Multiple Myeloma Through Bortezomib Dose Reduction With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving QOL in Multiple Myeloma With Bortezomib Dose Reduction: Rahul Banerjee and Gurbakhash Kaur At the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Rahul Banerjee, Editor in Chief of Oncology Data Advisor, sat down with Dr. Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas (UT) Southwestern Medical Center, to discuss their abstract about real-world dosing and prescribing patterns of bortezomib in newly diagnosed multiple myeloma. Dr. Banerjee and Dr. Kaur debate the pros and cons of once- versus twice-weekly dosing of bortezomib, its impact on tolerability and outcomes, and changes in trial design that are needed to make once-weekly dosing a new standard in clinical practice.  
Real-World Outcomes of Brexucabtagene Autoleucel for B-Cell ALL With Evandro Bezerra, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Real-World Outcomes of Brexuctabtagene Autoleucel for B-Cell ALL: Evandro Bezerra, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Evandro Bezerra, a Hematology Specialist at the Ohio State University Comprehensive Cancer Center, sat down with Oncology Data Advisor to discuss his team...
Investigating Therapies Targeting Cardiovascular Health in MDS With Diego Adrianzen Herrera, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Investigating Therapies Targeting Cardiovascular Health in MDS: Diego Adrianzen Herrera, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Diego Adrianzen Herrera, a Malignant Hematologist at the University of Vermont Medical Center, about his study investigating the impact of hypomethylating agents on cardiovascular disease risk for patients with myelodysplastic syndromes (MDS). Dr. Adrianzen Herrera explains the study's results and how they can be used to design future research around treatments targeting cardiovascular health in MDS.  
Improving Diversity in Multiple Myeloma Clinical Trials With Craig Cole, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving Diversity in Multiple Myeloma Clinical Trials: Craig Cole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Craig Cole, MD, Assistant Professor at Karmanos Cancer Institute, sat down with Oncology Data Advisor to share his passion for improving diversity in multiple myeloma clinical trials. He discusses the efforts that are currently underway to increase diverse accrual and the importance of raising awareness in order to address this issue both within the community and on a global scale.  
Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes With Claire Saxton, MBA
Keira Smith
Expert Analysis
Oncology Data Advisor® · Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes: Claire Saxton At the 2023 American Society of Hematology (ASH) Annual Meeting, Claire Saxton, Executive Vice President of Insights and Impact at Cancer Support Community, presented her team's study on communication that enables shared decision making in myelodysplastic syndromes (MDS). While there, she sat down with Oncology Data Advisor to discuss more about the results of the study and ways that health care professionals and patient advocacy groups can partner to ensure that clear and consistent messages are being delivered to patients with MDS so that they can be more informed and involved in their care.  
Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD   At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Brittany Ragon, Adult Leukemia and Transplant Specialist at Levine Cancer Institute, sat down with Oncology Data Advisor to discuss her pr...